AbCellera Biologics Inc.
ABCL
$4.24
-$0.23-5.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.24M | 5.05M | 6.51M | 7.32M | 9.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.24M | 5.05M | 6.51M | 7.32M | 9.95M |
| Cost of Revenue | 42.50M | 46.08M | 40.97M | 40.93M | 39.29M |
| Gross Profit | -38.26M | -41.03M | -34.46M | -33.60M | -29.33M |
| SG&A Expenses | 19.07M | 19.16M | 22.28M | 23.33M | 20.72M |
| Depreciation & Amortization | 5.33M | -19.44M | 36.92M | 36.52M | 4.84M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.90M | 45.81M | 100.17M | 100.78M | 64.85M |
| Operating Income | -62.66M | -40.76M | -93.66M | -93.45M | -54.89M |
| Income Before Tax | -52.98M | -46.83M | -62.63M | -48.19M | -42.75M |
| Income Tax Expenses | -7.36M | -12.62M | -11.53M | -11.26M | -2.14M |
| Earnings from Continuing Operations | -45.62M | -34.21M | -51.11M | -36.93M | -40.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.62M | -34.21M | -51.11M | -36.93M | -40.61M |
| EBIT | -62.66M | -40.76M | -93.66M | -93.45M | -54.89M |
| EBITDA | -57.33M | -26.04M | -56.74M | -56.93M | -50.05M |
| EPS Basic | -0.15 | -0.12 | -0.17 | -0.13 | -0.14 |
| Normalized Basic EPS | -0.11 | -0.06 | -0.17 | -0.10 | -0.09 |
| EPS Diluted | -0.15 | -0.12 | -0.17 | -0.13 | -0.14 |
| Normalized Diluted EPS | -0.11 | -0.06 | -0.17 | -0.10 | -0.09 |
| Average Basic Shares Outstanding | 297.69M | 295.52M | 294.85M | 294.22M | 292.72M |
| Average Diluted Shares Outstanding | 297.69M | 295.52M | 294.85M | 294.22M | 292.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |